Broadening the Tumor Antigens Panorama for Cancer Vaccines – All the Way to the Dark Matter of the Genome
Cet article passe en revue les principaux points abordés lors des 9èmes rencontres du "Think Tank" de Siena organisées en 2025, notamment l'évolution des vaccins antitumoraux des années 50 à aujourd'hui, les nouveaux vaccins émergents (agents épigénétiques, antigènes non canoniques), les enseignements pour le développement futur des médicaments, la conception des essais cliniques et les difficultés actuelles associées au développement
In recent decades the field of Tumor Antigens (TAs) has expanded and led to the discovery of non-canonical (“dark genome”) TAs. Such TAs may provide new opportunities for the development of cancer vaccines capable of inducing robust and durable antitumor immune responses. In addition to these improved vaccine concepts, the combination of novel vaccines with immune checkpoint inhibitors (ICI) may also improve immune responses and thus result in clinical benefit. While ICIs have shown to be useful combination agents for future vaccine development, the role of epigenetic modulators has not been fully appreciated. Recent discoveries suggest that epigenetic agents can reactivate non-canonical antigens. Thus, epigenetic modulators should be considered in future vaccine trials either in combination with ICIs or with vaccines.
European Journal of Cancer , article en libre accès, 2026